Department of Experimental and Clinical Medicine and DENOTHE Center, University of Florence, 50134, Florence, Italy.
Curr Allergy Asthma Rep. 2017 Sep 11;17(10):66. doi: 10.1007/s11882-017-0735-9.
The adaptive immune response orchestrated by type 2 T helper (Th2) lymphocytes, strictly cooperates with the innate response of group 2 innate lymphoid cells (ILC2), in the protection from helminths infection, as well as in the pathogenesis of allergic disease. The aim of this review is to explore the pathogenic role of ILC2 in different type 2-mediated disorders.
Recent studies have shown that epithelial cell-derived cytokines and their responding cells, ILC2, play a pathogenic role in bronchial asthma, chronic rhinosinusitis, and atopic dermatitis. The growing evidences of the contribution of ILC2 in the induction and maintenance of allergic inflammation in such disease suggest the possibility to target them in therapy. Biological therapies blocking ILC2 activation or neutralizing their effector cytokines are currently under evaluation to be used in patients with type 2-dominated diseases.
2 型 T 辅助（Th2）淋巴细胞协调的适应性免疫反应，与 2 类固有淋巴样细胞（ILC2）的固有反应严格合作，在抵御寄生虫感染以及过敏疾病发病机制中发挥作用。本综述旨在探讨 ILC2 在不同 2 型介导疾病中的致病作用。
最近的研究表明，上皮细胞衍生的细胞因子及其反应细胞 ILC2 在支气管哮喘、慢性鼻-鼻窦炎和特应性皮炎中发挥致病作用。ILC2 在这些疾病中诱导和维持过敏炎症中的作用的不断增加的证据表明，在治疗中靶向它们是可能的。目前正在评估阻断 ILC2 激活或中和其效应细胞因子的生物疗法，以用于 2 型主导疾病的患者。
